Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab — Margherita Rimini (2024) | RDL Network
Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab
Article 2024 en
Authors
MR
Margherita Rimini
BS
Bernardo Stefanini
TT
Toshifumi Tada
Abstract
1 min read
Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib.
Margherita Rimini, Margarida Montes, Elisabeth Amadeo, Francesco Vitiello, Masatoshi Kudo, Toshifumi Tada, Goki Suda, Shigeo Shimose, Sara Lonardi, Fabian Finkelmeier, Francesca Salani, Lorenzo Antonuzzo, Fabio Marra, Massimo Iavarone, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Rodolfo Sacco, Ilario Giovanni Rapposelli, Mario Scartozzi, P Nicoletta, Luca Aldrighetti, Mara Persano, Silvia Camera, Federico Rossari, Silvia Foti, Takashi Kumada, Atsushi Hiraoka, Hideki Iwamoto, Mario Domenico Rizzato, Vera Himmelsbach, Gianluca Masi, Mattia Corradi, Ciro Celsa, C. Fabio, Giovanni Luca Frassineti, Stefano Cascinu, Andrea Casadei‐Gardini, José Presa
Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima, Valentina Burgio, S. Shigeo, Toshifumi Tada, Goki Suda, Chi‐Hyeon Yoo, Jaekyung Cheon, David J. Pinato, Sara Lonardi, Mario Scartozzi, Massimo Iavarone, G.G. Di Costanzo, Fabio Marra, Caterina Soldà, Emiliano Tamburini, Fabio Piscaglia, Gianluca Masi, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta,
Discussion(0)
No comments yet. Be the first to comment.